Blue Cross & Blue Shield of MississippiCommercial · Coverage · Medical Policy · MS · Dermatology, Pediatrics, Family MedicineMedium impact
Ycanth (cantharidin)
Act
immediately
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
BCBS Mississippi has established that Ycanth (cantharidin) for treating molluscum contagiosum is considered not medically necessary as covered alternatives exist. All services related to delivery and administration will be denied without prior authorization approval through BCBSMS PA review process.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
01Billing team must flag HCPCS code J7354 (Cantharidin for topical administration) as requiring prior authorization through BCBSMS PA review process before treatment.
02Update billing system to prevent claims submission without PA approval.
03Providers should consider covered alternatives for molluscum contagiosum treatment.
04Claims submitted without prior authorization will be denied as not medically necessary.
Codes mentioned
J7354
Original notice
Ycanth (cantharidin)
bcbsms.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.